Legal & General Group
KYTX icon

Legal & General Group’s Kyverna Therapeutics KYTX Stock Holding History

Legal & General Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,769
Closed -$5.34K – 3564
2025
Q1 		$5.34K Hold
2,769
– – ﹤0.01% 3268
2024
Q4 		$10.4K Buy
2,769
+1,061
+62% +$5.08K ﹤0.01% 3246
2024
Q3 		$8.35K Sell
1,708
-5,681
-77% -$43.8K ﹤0.01% 3304
2024
Q2 		$55.4K Sell
7,389
-2,196
-23% -$33.5K ﹤0.01% 2783
2024
Q1 		$238K Buy
+9,585
New +$267K ﹤0.01% 2647

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group's KYTX Position: Q2 2025 in Review

Legal & General Group sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 2,769 shares — an estimated $5.34K sold.

Legal & General Group first reported a position in KYTX in Q1 2024 and held it in 5 quarters. The position peaked at $238K in Q1 2024. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • Legal & General Group reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 2,769 Kyverna Therapeutics shares in Q2 2025, an estimated $5.34K.
  • Legal & General Group first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 5 quarters.
  • Legal & General Group's Kyverna Therapeutics position peaked at $238K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.